Publications by authors named "Matthew Peery"
Article Synopsis
- - The objective of the review was to examine the pharmacology, safety, and effectiveness of BCMA-directed immunotherapies, such as CAR-T therapy and bispecific antibodies, for treating relapsed/refractory multiple myeloma (RRMM).
- - Evidence from phase III and II clinical trials shows that BCMA-directed therapies like idecabtagene vicleucel and teclistamab significantly improve response rates and progression-free survival compared to standard treatments for RRMM.
- - Despite their benefits, these therapies pose safety risks (like cytokine release syndrome) and face challenges in patient access due to the need for specialized administration and monitoring facilities.
Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first line chemoimmunotherapy, necessitating second-line salvage therapy. This has historically consisted of platinum-based chemotherapy regimens followed by autologous hematopoietic stem cell transplantation with curative intent for transplant-eligible patients or palliative chemotherapy for transplant-ineligible patients.
View Article and Find Full Text PDFThe present studies examined the biology of the multiple sclerosis drug dimethyl-fumarate (DMF) or its in vivo breakdown product and active metabolite mono-methyl-fumarate (MMF), alone or in combination with proteasome inhibitors, in primary human glioblastoma (GBM) cells. MMF enhanced velcade and carfilzomib toxicity in multiple primary GBM isolates. Similar data were obtained in breast and colon cancer cells.
View Article and Find Full Text PDF